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Accepted 11 December 2017; Published online 27 December 2017AbstractObjectives: Randomized controlled trials (RCTs) deliver robust internally valid evidence but generalizability is often neglected. Design
features built into the Prostate testing for cancer and Treatment (ProtecT) RCT of treatments for localized prostate cancer (PCa) provided
insights into its generalizability.
Study Design and Setting: Population-based cluster randomization created a prospective study of prostate-specific antigen (PSA)
testing and a comprehensive-cohort study including groups choosing treatment or excluded from the RCT, as well as those randomized.
Baseline information assessed selection and response during RCT conduct.
Results: The prospective study (82,430 PSA-tested men) represented healthy men likely to respond to a screening invitation. The
extended comprehensive cohort comprised 1,643 randomized, 997 choosing treatment, and 557 excluded with advanced cancer/comorbid-
ities. Men choosing treatment were very similar to randomized men except for having more professional/managerial occupations.
Excluded men were similar to the randomized socio-demographically but different clinically, representing less healthy men with more
advanced PCa.
Conclusion: The design features of the ProtecT RCT provided data to assess the representativeness of the prospective cohort and gener-
alizability of the findings of the RCT. Greater attention to collecting data at the design stage of pragmatic trials would better support later
judgments by clinicians/policy-makers about the generalizability of RCT findings in clinical practice.  2018 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Key findings
 Decisions taken when designing the ProtecT pros-
tate cancer (PCa) treatment trial and linked Cluster
randomized trial of PSA testing for prostate cancer
screening trial enabled the collection of data to
assess the representativeness of the prospective
study of prostate-specific antigen testing and
generalizability of the findings of the ProtecT RCT.
 Adding the extended comprehensive-cohort study
comprising all men diagnosed with PCa, including
those who chose a treatment or were ineligible for
the RCT with advanced cancer or comorbidities as
well as those randomized in ProtecT, allowed the
assessment of the generalizability of the trial’s
findings to patients diagnosed with PCa in routine
care.
What this adds to what was known?
 Aspects of the generalizability of pragmatic
RCTs can be evaluated through initiatives at
the design phase, such as assessing factors asso-
ciated with participation at various stages
through a preceding prospective study and/or
collecting data from those choosing treatments
or excluded from the trial according to eligibility
criteria, although these decisions will have time
and resource implications.
 Including an innovatively extended
comprehensive-cohort study of all men diagnosed
with a condition like PCa can enable assessment
of important similarities and differences between
the randomized group and those who choose a
treatment in standard practice or with aspects of
advanced cancer or comorbidities that preclude
trial participation, providing insights into the
applicability of the RCT to patients in routine
practice.
What is the implication and what should change
now?
 Greater attention should be devoted at the design
stage of pragmatic RCTs to ensure that appropriate
data are collected to support later judgments by cli-
nicians and policy-makers about the generaliz-
ability of the findings of an RCT to patients in
routine clinical practice.1. Introduction
1.1. Pragmatic RCTs and generalizability
Randomized controlled trials (RCTs) offer the most
rigorous way to evaluate the effectiveness of treatments,
but there are often concerns about the generalizability of
findings [1e3]. A real or perceived lack of relevance to pa-
tients in routine care contributes to the slow or limited up-
take of RCT evidence into practice [4,5]. RCTs remain the
primary design for evaluation because random allocation of
participants to treatment groups helps ensure against selec-
tion bias. Whether and to what degree the findings of an
RCT can then be generalized to patients in similar or
different settings or with different but related disease char-
acteristics requires judgments, including reflection on the
evidence from a new study in relation to prior knowledge,
statistical reasoning, biological plausibility, and interpreta-
tions of the impact of eligibility criteria of the RCT in the
context of contemporary clinical practice [3].
Decisions at the design stage of an RCT can facilitate
or inhibit later judgments about the generalizability and
clinical relevance of the findings. The PRagmatic Explan-
atory Continuum Indicator Summary-2 (PRECIS-2) tool
was developed to support trialists in making decisions
to position an RCT along the continuum between explan-
atory efficacy approaches in ideal circumstances and
pragmatic designs evaluating effectiveness within ‘‘real-
world’’ naturalistic settings [6]. There is consensus about
the value of pragmatic designs in informing clinical
decision-making, but there has been considerable recent
debate in this journal about how best to design such RCTs
and the role of the PRECIS-2 tool [7e11]. In addition, a
recent series has sought to provide theoretical and prac-
tical guidance to promote operational feasibility in prag-
matic RCTs [12,13].
Pragmatic RCTs need to closely resemble the popula-
tion and clinical practice they aim to influence to ensure
they retain the advantages of randomization while adding
the ability to produce findings that are generalizable.
However, during the implementation of such RCTs,
unanticipated challenges often arise in relation to recruit-
ment, setting, equipoise, or other aspects of RCT
conduct, or changes in clinical practice [10]. Judgments
about the generalizability of an RCT require knowledge
about local health and care conditions, and trialists
may not be best placed to do this [7]. To ensure that
evidence-based judgments can be made, trialists also
need to ensure that their design allows the collection of
data that will later facilitate the assessment of the RCT
findings’ generalizability and clinical relevance. We
were able to collect such data in linked RCTs in the area
of prostate cancer (PCa).
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cancer
PCa is a major cause of death for older men, and
although the prostate-specific antigen (PSA) blood test pro-
vides the opportunity to identify the disease at a stage when
it could be cured, screening detects many tumors that will
not become clinically important and so receive unnecessary
radical/curative treatments that cause damaging side-
effects. Previously published RCTs have focused either
on screening or treatment and have contributed valuable
knowledge but not provided consistent findings [14e17].
In the mid/late 1990s, we designed two interlinked prag-
matic RCTs aiming to inform policy for PCa screening
and treatment practice:
(a) Cluster randomized trial of PSA testing for prostate
cancer (CAP): The Cancer Research UK/UK Depart-
ment of Health, CAP employed cluster randomization
of general practices in a Zelen design to create an
intervention arm comprising a prospective study ofCAP trial intervenƟon arm:
ProtecT prospecƟve study of
PSA tesƟng
228,966
invited to aƩend clinic appointment
16,104
5,954 r
100,444
aƩended appointment
7,664 in
10,350
82,430
received a PSA test
73,538
280 PSA
46 no r
7,414
received a prostate biopsy
1,152 d
2,896
diagnosed with prostate cancer
CAP trial
Cluster randomizaƟon of general pracƟces
122,502
Responded to invitaƟon
106,46
4,518 n
inconcl
Fig. 1. CAP trial framework and comparison points in the ProtecT prospecti
CAP, Cluster randomized trial of PSA testing for prostate cancer.men undergoing PSA testing and a control arm of
usual National Health Service (NHS) care without
organized PSA testing (Fig. 1; baseline details [18]).
(b) ProtecT: The National Institute for Health Research,
ProtecT (Prostate testing for cancer and Treatment)
RCT evaluated the effectiveness and cost-
effectiveness of the three major standard treatments
for clinically localized PCa diagnosed during the pro-
spective study of PSA testing: radical surgery, radical
external-beam radiotherapy, and active monitoring
(Fig. 1; baseline details [19]).
These RCTs were intended to be pragmatic in design,
and knowing that the primary outcomes would not be pub-
lished until a median of 10 years’ follow-up, decisions were
taken at the design stage to provide data to facilitate the
later evaluation of the generalizability and clinical rele-
vance of the findings.
Initially, a feasibility study was undertaken to investigate
whether it was possible to recruit men from the community toComparison
1
CAP trial control arm:
Usual pracƟce
2
did not aƩend
efused to aƩend
3
eligible
declined to parƟcipate
4
PSA <3ng/ml
>19.99ng/ml
esult
5
eclined prostate biopsy
using Zelen design
4 non-responders
o cancer (biopsy negaƟve or
usive)
ve study of PSA testing and diagnosis. PSA, prostate-specific antigen;
38 J.L. Donovan et al. / Journal of Clinical Epidemiology 96 (2018) 35e46have a PSA test and then randomize those diagnosed with
clinically localized PCa into a treatment trial. When this
feasibility was assured [20], the CAP RCT was initiated to
evaluate screening. The population-based cluster design of
CAP created an intervention arm comprising a prospective
study of PSA testing within which the ProtecT RCTof treat-
ments was embedded (Fig. 1). As recruitment to ProtecTwas
anticipated to be particularly challenging because of random-
ization between surgery, radiotherapy or no immediate treat-
ment (active monitoring), an integrated recruitment study
was undertaken [21] and a comprehensive-cohort study as
in [22] to follow-up men who declined randomization and
chose a treatment alongside those who agreed to be random-
ized. The comprehensive cohortwas then extended to include
all men diagnosed with PCa during the prospective study but
excluded from the treatment trial because of advanced PCa or
comorbiditydmany of these men would have received one
of the study treatments in usual practice (although theywould
not be eligible for all three as in the RCT).
The collection of individual participant socio-
demographic, symptomatic, and clinical data at baseline
in the prospective study of PSA testing enabled the inves-
tigation of the representativeness of the study population
and selection factors at each stage of response and clinical
eligibility. These data provide information to enable judg-
ments about the generalizability and clinical relevance of
the findings of the recently published ProtecT primary out-
comes [23,24]. This article presents the data generated by
the CAP/ProtecT design features, their limitations, and
the insights that they can provide; with brief consideration
of the value and practicality of such design features in
pragmatic RCTs more generally to inform assessments of
generalizability.2. Methods
2.1. The CAP randomized controlled trial
Cluster randomization of more than 900 primary-care
centers in the UK created an intervention arm of men aged
50e69 years invited to PSA testing and a control arm of usual
NHS care without organized PSA testing, followed-up using
routinely collected mortality data [18] (Fig. 1). There was no
evidence of differences between primary-care centers
agreeing or declining to participate in CAP or between men
in the intervention and control practices [25]. The CAP inter-
vention arm provided a population-based framework for the
recruitment of men into the prospective study of PSA testing
and ProtecT treatment RCT.
2.2. ProtecT prospective study of PSA tesing
Men aged 50e69 years registered in primary-care cen-
ters were sent one invitation to attend an appointment to
discuss PSA testing and the ProtecT RCT. Data available
to compare responders and nonresponders to theappointment and PSA testing were restricted to date of birth
and postcode. While men who responded to the invitation
were similar to nonresponders, except for being slightly
less deprived [26], data to evaluate more detailed character-
istics of nonresponders were not available. Men attending
an appointment who consented to a blood test for PSA
had socio-demographic and clinical history information
collected and completed a brief study questionnaire, with
a more detailed questionnaire requested from men later un-
dergoing prostate biopsies [27]. Comparisons were made
between those participating or not at each stage through
exclusion or choice, to provide insights about representa-
tiveness and generalizability.
2.3. ProtecT RCT recruitment and comprehensive-
cohort study
Men diagnosed with clinically localized PCa through the
PSA-testing study and meeting the inclusion/exclusion
criteria were eligible for recruitment to the ProtecT RCT.
They attended an appointment with an urologist for the
diagnosis and basic information and received detailed infor-
mation about treatment options and the ProtecT RCT from
a research nurse. Men were asked if they would consent to
random allocation of treatment. If they declined randomiza-
tion, they chose a treatment and were included in the
comprehensive cohort (Fig. 2), followed-up identically to
the randomized.
2.4. ProtecT extended comprehensive-cohort study
Men diagnosed with PCa but excluded from the RCT
because they had advanced cancer or were not eligible
for all three treatments were included in the extended
comprehensive cohort (Fig. 2).
2.5. Statistical analysis
Socio-demographic information and data from the partic-
ipant questionnaires were used to compare the baseline char-
acteristics of the men at different stages of response and
eligibility in the prospective PSA-testing study to assess
response and selection (comparisons 1e5 Fig. 1) and to
compare the randomized group with those choosing their
treatment, diagnosed with advanced cancer or excluded from
the RCT for other reasons (comparisons 6e8, Fig. 2).
All statistical analyses were completed using STATA,
version 14.1. For continuous socio-demographic variables,
medians and interquartile ranges were reported with Man-
neWhitney tests to analyze differences between groups.
Questionnaire data were presented with means and standard
deviations. Between-group comparisons were carried out to
investigate whether baseline characteristics differed between
those proceeding through PSA testing and PCa diagnosis or
excluded or choosing not to participate in the prospective
cohort; and between the randomized and other groups in
the extended comprehensive cohort. With ceiling effects
3,221 diagnosed with prostate cancer
(2,896 main trial prospecƟve study,
325 feasibility study)
2,664 localized prostate cancer
Eligible for inclusion in trial
ProtecT treatment trial
1,643 randomized
Excluded from ProtecT trial
267 with advanced prostate cancer (‘advanced’ group)
290 with other criteria (‘excluded other’ group)
997 chose treatment (‘preference’ group)
[24 randomized in disconƟnued two-arm study]
Comparison
6
7
8
Fig. 2. ProtecT RCT extended comprehensive-cohort study and comparison points. ProtecT, prostate testing for cancer and treatment; RCT, ran-
domized controlled trial.
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using a nonparametric ManneWhitney test. For binary vari-
ables, such as previous PSA test, groups were compared us-
ing logistic regression. Ordered categorical variables such as
occupation and cancer staging were analyzed using ordinal
logistic regression with the most-desirable/least-worse cate-
gory as the base comparator. Adjustment for age and center
in the logistic and ordinal logistic models did not influence
overall conclusions. Given the sample size and large number
of tests, greater attention was given to descriptive statistics
rather than P-values: for continuous variables, we considered
with interest but caution differences 0.5 standard devia-
tions; similarly for categorical variables with differences that
resulted in a risk ratio of 0.9.3. Results
3.1. Prospective study of PSA testing and PCa diagnosis
In total, 122,502 men responded to the invitation for a
PSA test, and 100,444 attended. Those who explicitly
refused to attend (5,954) or did not attend after agreeing
to do so (16,104) lived in more deprived areas than at-
tenders (comparison 1, Fig. 1, Table Web 1 on the journal’s
website at www.elsevier.com). Men who attended but
declined the PSA test (10,350) or were ineligible (7,665)
also lived in more deprived areas than those who attended
(comparison 2, Fig. 1). Eighty-two thousand four hundred
thirty men attended and received a PSA test (36% of those
invited) (Fig. 1, Tables 1 and 2 and Web 1 on the journal’s
website at www.elsevier.com).
At each of the stages of PSA testing, biopsy, and PCa
diagnosis, the groups eligible for the RCTwere very similar
to those excluded in terms of socio-demographic character-
istics (comparisons 3e5 Fig. 1). Expected clinical relation-
ships were found, such as a positive relationship between
PSA and age, and weak evidence for family history of
the disease and diagnosis (Table 1). It was notable that
those more likely to have a high PSA-test result ordiagnosis of PCa were less likely to have previously had
a PSA test or urological treatment (Table 1).3.2. ProtecT recruitment and comprehensive cohort
Overall, 3,221 men were diagnosed with PCa: 2,896 in
the prospective study and 325 during the feasibility phase
(Fig. 2). A total of 2,664 (83%) had clinically localized
PCa (stage T1/T2) and were eligible for inclusion in the
ProtecT RCT. An integrated recruitment study was under-
taken to understand the issues underlying recruitment diffi-
culties and provide improvements to study information and
presentation. This increased the percentage consenting to
randomization from 30% in the early stages to 62% at
completion [21]. The comprehensive cohort comprised:
 ProtecT randomized cohort: 1,643 men (62%) who con-
sented to randomization to the ProtecT RCT comparing
active monitoring, surgery, and radiotherapy.
 ProtecT ‘‘treatment-choice’’ cohort: 997 men (38%)
who declined randomization and chose their treatment
(273 surgery, 133 radiotherapy, 529 active monitoring,
and 62 other options not included in the RCT [brachy-
therapy and high-frequency ultrasound]).
The ‘‘treatment-choice’’ group was very similar to the ran-
domized in relation to clinical and socio-demographic charac-
teristics, except that those who chose treatment were more
likely to be in managerial/professional occupations than the
randomized (53% vs. 42%), less deprived (11% vs. 15%)
(Table 3), and more likely to have had a previous PSA test
(18% vs. 14%). The groups were almost identical in response
to general health measures and symptom scores (Table 4).3.3. Extended comprehensive-cohort study
The following were excluded from randomization:
 Two hundred sixty-seven (8%) with advanced cancer
(stage T3 or higher).
Table 1. Baseline differences in socio-demographic and clinical factors for participants in the ProtecT prospective study of PSA testing and cancer
diagnosis
Had a PSA testa n [ 82,430
PSA !3
n [ 73,538
PSA ‡20
n [ 280
Trial eligible PSA (3 £ PSA ! 20) n [ 8,566
All eligible
n [ 8,566
Declined
biopsy
n [ 1,152
Biopsy n [ 7,414
Received biopsy
n [ 7,414
Negative
n [ 4,518
Positive
n [ 2,896
Age (n) 73,538 280 8,566 1,152 7,414 4,518 2,896
Median age (IQR) 58.0 (8.0)b 64.0 (7.0) 62.0 (8.0)b 62.0 (8.0) 62.0 (8.0) 61.0 (8.0) 62.0 (8.0)
P value P ! 0.001c P ! 0.001d P ! 0.001e P ! 0.001f
Ethnicity
White n (%) 71,948 (98) 265 (96) 8,377 (99) 1,113 (98) 7,264 (99) 4,425 (99) 2,839 (99)
Other n (%) 1,127 (2) 10 (4) 108 (1) 23 (2) 85 (1) 52 (1) 33 (1)
P value P 5 0.055c P 5 0.001d P 5 0.017e P 5 0.961f
Marital status
Married/living as
married n (%)
61,507 (84) 226 (82) 7,091 (83) 941 (83) 6,150 (84) 3,730 (83) 2,420 (84)
Other (divorced) n
(%)
11,641 (16) 49 (18) 1,410 (17) 198 (17) 1,212 (16) 755 (17) 457 (16)
P value P 5 0.110c P 5 0.589d P 5 0.437e P 5 0.284f
Occupation present or last paid
Managerial n (%) 9,948 (44) 106 (41)b 3,783 (46)b 499 (49) 3,284 (46) 2,024 (47) 1,260 (44)
Intermediate n
(%)
3,886 (17) 44 (17) 1,351 (16) 155 (15) 1,196 (17) 734 (17) 462 (16)
Working n (%) 8,717 (39) 110 (42)b 3,067 (37)b 355 (35) 2,712 (38) 1,588 (37) 1,124 (39)
P value P 5 0.005c P 5 0.073d P 5 0.036e P 5 0.018f
Cancer/treatment history
Previous PSA test
(%)
9,229 (13)b 17 (6)b 1,594 (19)b 279 (25)b 1,315 (18)b 892 (20)b 423 (15)b
P value P ! 0.001c P ! 0.001d P ! 0.001e P ! 0.001f
Previous urinary/
prostate
treatment (%)
5,980 (8)b 24 (9)b 1,069 (13)b 171 (15)b 898 (12)b 644 (14)b 254 (9)b
P value P ! 0.001c P 5 0.058d P 5 0.007e P ! 0.001f
Family history of
cancer (prostate
only) (%)
3,748 (6)b 17 (7) 554 (7)b 70 (7) 484 (7) 264 (7)b 220 (9)b
P value P ! 0.001c P 5 0.765d P 5 0.652e P 5 0.002f
Family history of
cancer (all) (%)
36,541 (53) 144 (57) 4,445 (56) 569 (54) 3,876 (56) 2,320 (55) 1,556 (57)
P value P ! 0.001c P 5 0.567d P 5 0.177e P 5 0.030f
Deprivation score
(overall n)
73,027 279 8,488 1,143 7,345 4,484 2,861
Living in an area
of deprivation n
(%)
10,016 (14) 34 (12) 1,097 (13) 152 (13) 945 (13) 538 (12)b 407 (14)b
P value P 5 0.044c P 5 0.718d P 5 0.685e P 5 0.005f
PSA level at baseline
(n)
73,538 280 8,566 1,152 7,414 4,518 2,896
Median PSA level
(IQR)
0.9 (0.9)b 32.1 (29.0)b 4.2 (2.5)b 3.9 (2.0) 4.3 (2.5) 4.1 (2.0) 4.8 (3.4)
P value P ! 0.001e P ! 0.001f
Abbreviations: IQR, interquartile range; ProtecT, prostate testing for cancer and treatment; PSA, prostate-specific antigen; RR, risk ratio.
a Forty-six men had no result.
b Differences of interest when using the 0.5 SDS cutoff for continuous outcomes or the 0.9 RR cutoff for categorical outcomes.
c Comparison between PSA !3 and eligible PSA.
d Comparison between PSA 20 and eligible PSA.
e Comparison between those who had a biopsy and those who did not.
f Comparison between those with a negative biopsy result and those with a positive biopsy result.
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ered unsuitable for the treatments for other reasons,
mostly comorbidities.As expected, the 267 ‘‘advanced cancer’’ group had
much higher PSA levels, cancer stage (95% T3), and PCa
grade (71% Gleason 7 or more) than those randomized
Table 2. Patient-reported general health and symptomatic measures: baseline differences for participants in the ProtecT prospective study of PSA
testing
Had a PSA testa n [ 82,430
PSA !3
n [ 73,538
PSA ‡20
n [ 280
Trial eligible PSA (3 £ PSA ! 20) n [ 8,566
All eligible
n [ 8,566
Declined
biopsy
n [ 1,152
Biopsy n [ 7,414
Received biopsy
n [ 7,414
Negative
n [ 4,518
Positive
n [ 2,896
SF-12 (minimum n) 60,146 225 6,925 902 6,023 3,710 2,313
Mean physical score (SD) 49.6 (9.0) 49.5 (9.2) 49.4 (9.0) 48.6 (9.6) 49.5 (8.9) 49.7 (8.8) 49.3 (9.0)
P value P 5 0.029b P 5 0.764c P 5 0.028d P 5 0.070e
Mean mental score (SD) 53.2 (8.4) 54.3 (7.8) 53.8 (7.8) 53.9 (8.1) 53.8 (7.8) 53.8 (7.8) 53.8 (7.8)
P value P ! 0.001b P 5 0.205c P 5 0.219d P 5 0.715e
HADS (minimum n) 60,917 238 7,241 960 6,281 3,818 2,459
Anxiety case (8) n (%) 13,882 (23)f 46 (19) 1,413 (20)f 168 (17)f 1,245 (20)f 749 (20) 496 (20)
P value P ! 0.001b P 5 0.920c P 5 0.086d P 5 0.613e
Depression case (8) n (%) 4,905 (8)f 13 (5)f 508 (7)f 80 (8)f 428 (7)f 244 (6)f 184 (7)f
P value P 5 0.002c P 5 0.356c P 5 0.087d P 5 0.092e
Mean anxiety score (SD) 5.2 (3.5) 4.5 (3.5) 4.9 (3.4) 4.7 (3.5) 4.9 (3.3) 4.9 (3.3) 5.0 (3.4)
P value P ! 0.001c P 5 0.040c P 5 0.026d P 5 0.420e
Mean depression score (SD) 3.1 (2.8) 3.0 (2.7) 3.0 (2.7) 3.0 (3.0) 3.0 (2.6) 2.9 (2.6) 3.1 (2.7)
P value P 5 0.012c P 5 0.912c P 5 0.299d P 5 0.076e
EQ5D (n) 66,332 257 7,744 1,020 6,724 4,076 2,648
Mean EQ5D score 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.9 (0.2)
P value P 5 0.040c P 5 0.854c P 5 0.499d P 5 0.003e
ICSmaleSF e symptoms
(minimum n)
67,084 258 7,883 1,028 6,851 4,173 2,678
Delay before urinating n (%) 29,642 (44)f 136 (52) 4,340 (55)f 522 (50) 3,818 (55) 2,435 (58)f 1,383 (51)f
P value P ! 0.001c P 5 0.340c P 5 0.003d P ! 0.001e
Rush to the toilet n (%) 30,586 (45)f 135 (51)f 4,549 (57)f 554 (53) 3,995 (58) 2,546 (60)f 1,449 (54)f
P value P ! 0.001b P 5 0.051c P 5 0.003d P ! 0.001e
Leak before reaching the toilet
n (%)
13,932 (21)f 82 (31) 2,246 (28)f 279 (27) 1,967 (29) 1,298 (31)f 669 (25)f
P value P ! 0.001b P 5 0.323c P 5 0.225d P ! 0.001e
Frequency (3 h per void) n (%) 43,699 (65) 171 (66) 5,496 (70) 686 (66) 4,810 (70) 2,994 (72) 1,816 (68)
P value P ! 0.001b P 5 0.238c P 5 0.015d P 5 0.001e
Nocturia n (%) 45,310 (67)f 183 (70) 5,915 (75)f 756 (74) 5,159 (75) 3,167 (76) 1,992 (74)
P value P ! 0.001b P 5 0.059c P 5 0.245d P 5 0.196e
Do urinary symptoms interfere
with life? n (%)
13,466 (20)f 60 (23)f 2,272 (29)f 270 (26)f 2,002 (29)f 1,355 (32)f 647 (24)f
P value P ! 0.001b P 5 0.037c P 5 0.032d P ! 0.001e
Abbreviations: IQR, interquartile range; ProtecT, prostate testing for cancer and treatment; PSA, prostate-specific antigen; SD, standard devi-
ation; RR, risk ratio; SF-12, Short-form 12-item questionnaire; EQ5D, Euroqol 5 dimension scale.
a Forty-six men had no result.
b Comparison between PSA !3 and eligible PSA.
c Comparison between PSA 20 and eligible PSA.
d Comparison between those who had a biopsy and those who did not.
e Comparison between those with a negative biopsy result and those with a positive biopsy result.
f Differences of interest when using the 0.5 SDS cutoff for continuous outcomes or the 0.9 RR cutoff for categorical outcomes.
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in terms of socio-demographic characteristics and health
and symptom scores, although much less likely to have
had a previous PSA test (7% vs. 14%) (Table 3). The 290
‘‘excluded other’’ group had higher grade (37% vs. 23%
Gleason 7 or higher) and stage (38% vs. 24% T2) PCa than
those randomized, although not as high as the ‘‘advanced
cancer’’ men. They were similar to the randomized group
in terms of socio-demographic characteristics and clinical
history, although more likely to have had previous urologi-
cal treatment (Table 3) and as expected, slightly poorer
health status with more depression and some worse urinary
symptoms (Table 4) (Fig. 2, Tables 3 and 4).4. Discussion
The major aim of pragmatic RCTs is to produce findings
that are clinically relevant and generalizable beyond the
specific participants. The ProtecT RCT was designed to
evaluate the effectiveness of treatments for clinically local-
ized PCa and was embedded in the intervention arm of the
CAP RCT evaluating population screening. The ProtecT
RCT was designed in the late 1990s, more than 15 years
before the results were published [23,24], aiming to be
pragmatic and with design features that provided opportu-
nities to collect data that can now be used to produce in-
sights into the representativeness of the PSA-tested cohort
Table 3. Baseline differences in socio-demographic and clinical factors for those participating in the ProtecT RCT extended comprehensive-cohort
study
Randomized
n [ 1,643
Advanced
n [ 267
Excluded (other)
n [ 290
Choosing
treatment n [ 997
Age (n) 1,643 267 290 997
Median age (IQR) 62.0 (9.0) 63.0 (8.0) 63.0 (8.0) 62.0 (7.0)
P value P 5 0.001a P ! 0.001b P 5 0.604c
Ethnicity
White n (%) 1,606 (99) 259 (99) 283 (99) 984 (99)
Other n (%) 22 (1) 3 (1) 3 (1) 9 (1)
P value P 5 0.786a P 5 0.679b P 5 0.310c
Marital status
Married/living as married n (%) 1,375 (84) 231 (88) 232 (81) 841 (85)
Other (e.g. divorced) n (%) 257 (16) 31 (12) 56 (19) 151 (15)
P value P 5 0.103a P 5 0.118b P 5 0.719c
Occupation present or last paid
Managerial n (%) 684 (42)d 107 (42) 121 (44) 516 (53)d
Intermediate n (%) 259 (16)d 45 (18) 46 (17) 157 (16)d
Working n (%) 678 (42)d 104 (41) 111 (40) 307 (31)d
P value P 5 0.898a P 5 0.589b P ! 0.001c
Cancer/treatment history
Previous PSA test (%) 227 (14)d 19 (7)d 37 (13) 175 (18)d
P value P 5 0.004a P 5 0.720b P 5 0.012c
Previous urinary/prostate treatment (%) 142 (9)d 26 (10)d 36 (13)d 82 (8)d
P value P 5 0.510a P 5 0.040b P 5 0.694c
Family history of cancer (prostate only) (%) 119 (8)d 19 (9)d 21 (8) 83 (9)d
P value P 5 0.829a P 5 0.926b P 5 0.271c
Family history of cancer (all) (%) 897 (58) 131 (55) 144 (54) 543 (58)
P value P 5 0.388a P 5 0.235b P 5 0.885c
Deprivation score (n) 1,624 262 285 977
Living in an area of deprivation n (%) 239 (15)d 39 (15) 44 (15) 111 (11)d
P value P 5 0.943a P 5 0.752b P 5 0.015c
PSA level (minimum n) 1,631 167 198 876
Median baseline PSA level (IQR) 4.6 (3.1)d 8.5 (8.0)d 5.2 (4.8) 4.8 (3.1)
P value P ! 0.001a P 5 0.002b P 5 0.455c
Median biopsy PSA level (IQR) 4.8 (3.4)d 9.1 (8.8)d 5.9 (4.8) 4.8 (3.3)
P value P ! 0.001a P ! 0.001b P 5 0.714c
Gleason score
6 (%) 1,266 (77)d 75 (28)d 181 (63)d 755 (76)
7 (%) 339 (21)d 140 (52)d 86 (30)d 218 (22)
8e10 (%) 37 (2)d 52 (19)d 19 (7)d 24 (2)
P value P ! 0.001a P ! 0.001b P 5 0.419c
Cancer staging
T1| (%) 1,249 (76)d 5 (2)d 172 (61)d 758 (76)
T2 (%) 394 (24)d 3 (1)d 106 (38)d 239 (24)
T3^(%) 0 (0)d 250 (95)d 3 (1)d 0 (0)
T4þ (%) 0 (0)d 4 (2)d 0 (0)d 0 (0)
P value P ! 0.001a P ! 0.001b P 5 0.996c
Risk categorizatione
Low (%) 951 (58) 0 (0) 110 (38) 559 (56)
Intermediate (%) 654 (40) 215 (81) 159 (55) 414 (42)
High (%) 37 (2) 52 (19) 19 (7) 24 (2)
P value P ! 0.001a P ! 0.001b P 5 0.350c
Abbreviations: ProtecT, prostate testing for cancer and treatment; PSA, prostate-specific antigen; RCT, randomized controlled trial; RR, risk ratio.
|Includes 18 ‘‘T1/T2’’ in the advanced or excluded other group;^includes two ‘‘T3/T4’’ in the advanced or excluded other group.
a Comparison between randomized and advanced men.
b Comparison between randomized and excluded men.
c Comparison between randomized and preference men.
d Differences of interest when using the 0.5 SDS cutoff for continuous outcomes or the 0.9 RR cutoff for categorical outcomes.
e Defined as ‘‘low’’ if T1 and G 6 and PSA !10, ‘‘high’’ if G 8, ‘‘intermediate’’ for all other combinations of stage, grade, and PSA.
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50e69 years and the generalizability of the ProtecT
treatment RCT findings to patients diagnosed with PCa in
clinical practice.The CAP cluster randomization of primary-care prac-
tices created comparable intervention and control arms,
and so men invited to the prospective study of PSA testing
were representative of the population of men aged
Table 4. Patient-reported general health and symptomatic measures: baseline differences for those participating in the ProtecT RCT extended
comprehensive-cohort study
Randomized
n [ 1,643
Advanced
n [ 267
Excluded
(other) n [ 290
Choosing treatment
n [ 997
SF-12 (minimum n) 1,260 172 190 778
Mean physical score (SD) 51.2 (7.9) 50.0 (8.7) 47.6 (10.8) 51.3 (7.9)
P value P 5 0.142a P ! 0.001b P 5 0.464c
Mean mental score (SD) 53.9 (7.5) 53.4 (8.4) 53.4 (8.9) 53.5 (8.2)
P value P 5 0.982a P 5 0.875b P 5 0.974c
HADS (minimum n) 1,399 201 228 853
Anxiety case (8) n (%) 278 (20) 47 (23) 51 (22) 180 (21)
P value P 5 0.317a P 5 0.373b P 5 0.504c
Depression case (8) n (%) 80 (6)d 12 (6) 21 (9)d 44 (5)d
P value P 5 0.886a P 5 0.045b P 5 0.572c
Mean anxiety score (SD) 4.9 (3.5) 5.2 (3.8) 5.1 (3.8) 4.9 (3.5)
P value P 5 0.328a P 5 0.531b P 5 0.933c
Mean depression score (SD) 2.5 (2.5) 2.6 (2.8) 3.2 (3.1) 2.5 (2.6)
P value P 5 0.844a P 5 0.001b P 5 0.886c
EQ5D (n) 1,413 206 224 854
Mean EQ5D score 0.9 (0.2)d 0.9 (0.2) 0.8 (0.2)d 0.9 (0.2)
P value P 5 0.022a P ! 0.001b P 5 0.260c
ICSmaleSF e symptoms (minimum n) 1,410 208 230 856
Delay before urinating n (%) 725 (51) 101 (48) 130 (56) 422 (49)
P value P 5 0.388a P 5 0.160b P 5 0.387c
Rush to the toilet n (%) 844 (59) 137 (65) 149 (64) 502 (58)
P value P 5 0.098a P 5 0.199b P 5 0.596c
Leak before reaching the toilet n (%) 407 (29)d 72 (34)d 81 (35)d 206 (24)d
P value P 5 0.081a P 5 0.060b P 5 0.015c
Frequency (2 h per void) n (%) 460 (33) 66 (32) 72 (31) 245 (30)
P value P 5 0.797a P 5 0.632b P 5 0.143c
Nocturia (O1 per night) n (%) 312 (22)d 63 (30)d 65 (28)d 166 (19)d
P value P 5 0.010a P 5 0.034b P 5 0.147c
Do urinary symptoms interfere with life? n (%) 367 (26) 58 (28) 66 (28) 211 (24)
P value P 5 0.531a P 5 0.401b P 5 0.489c
ICSmaleSF scales (minimum n) 1,413 207 231 854
Mean ICSmaleVS (voiding scale) 3.3 (3.0) 3.2 (3.1) 3.8 (3.6) 3.3 (3.3)
P value P 5 0.549a P 5 0.157b P 5 0.310c
Mean ICSmaleIS (incontinence scale) 1.8 (1.9) 1.9 (1.8) 2.2 (2.2) 1.6 (1.7)
P value P 5 0.668a P 5 0.074b P 5 0.087c
ICIQ (n) 1,244 174 202 757
Mean ICIQ (SD) 1.3 (2.3) 1.3 (2.2) 1.6 (2.6) 1.0 (2.1)
P value P 5 0.817a P 5 0.093b P 5 0.017c
ICIQ QoL impact: none (%) 1,174 (93) 168 (94) 183 (89) 725 (95)
ICIQ QoL impact: moderate (%) 81 (6) 11 (6) 22 (11) 39 (5)
ICIQ QoL impact: high (%) 4 (!1) 0 (0) 0 (0) 1 (!1)
P value P 5 0.754a P 5 0.046b P 5 0.167c
EPIC urinary (minimum n) 745 112 124 503
Urinary summary 92.7 (9.1) 93.3 (8.1) 91.3 (10.5) 93.6 (8.2)
P value P 5 0.619a P 5 0.163b P 5 0.205c
Urinary function 95.1 (8.4) 95.7 (6.7) 94.4 (8.7) 96.3 (7.0)
P value P 5 0.826a P 5 0.339b P 5 0.006c
Urinary bother 91.0 (11.7) 91.3 (11.6) 89.2 (13.6) 91.6 (10.6)
P value P 5 0.758a P 5 0.122b P 5 0.987c
Incontinence 93.0 (11.3) 93.8 (9.6) 91.3 (12.7) 94.7 (9.8)
P value P 5 0.782a P 5 0.128b P 5 0.012c
Irritative/obstructive 93.0 (9.2) 93.5 (8.4) 91.8 (10.4) 93.3 (8.4)
P value P 5 0.633a P 5 0.186b P 5 0.982c
EPIC bowel (minimum n) 748 113 126 509
Bowel summary 93.6 (8.4) 92.8 (8.4) 92.0 (9.9) 94.0 (7.2)
P value P 5 0.141a P 5 0.024b P 5 0.843c
Bowel function 92.0 (8.8) 91.5 (8.2) 90.5 (9.2) 92.4 (7.9)
P value P 5 0.335a P 5 0.065b P 5 0.436c
Bowel bother 95.1 (10.0) 93.9 (11.1) 93.0 (14.1) 95.6 (8.5)
P value P 5 0.122a P 5 0.110b P 5 0.958c
Abbreviations: ProtecT, prostate testing for cancer and treatment; QoL, quality of life; RCT, randomized controlled trial; SD, standard deviation;
SF-12, Short-form 12-item questionnaire; EQ5D, Euroqol 5 dimension scale; ICIQ, International Consultation on Incontinence Questionnaire;
EPIC, Expanded Prostate Cancer Index Composite.
a Comparison between randomized and advanced men.
b Comparison between randomized and excluded men.
c Comparison between randomized and preference men.
d Differences of interest when using the 0.5 SDS cutoff for continuous outcomes or the 0.9 RR cutoff for categorical outcomes.
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vented access to data from potential participants who did
not respond to the invitation to PSA testing or would have
been excluded with serious comorbidities by primary-care
physicians. Those who attended for PSA testing were prob-
ably representative of healthy men aged 50e69 years likely
to respond to screening, rather than all men of the same
age. While this would not seriously affect the generaliz-
ability of the ProtecT RCT to men fit for radical treatments,
it remains a limitation in relation to the wider range of men
diagnosed with PCa in routine practice. Extending the
comprehensive cohort enabled follow-up of some less-fit
men and those with more advanced disease.
The prospective study of PSA testing served as a recruit-
ment framework for the ProtecT treatment RCT, and baseline
data collected during testing and PCa diagnosis allowed the
exploration of response and clinical factors that might affect
the generalizability of the RCT findings. Very few differ-
ences were evident between eligible and ineligible groups
(other than expected clinical factors), although men who
declined diagnostic tests were slightly more materially
deprived than consenters. Similarly, in the comprehensive
cohort, men who chose treatments (‘‘treatment-choice’’
group) were more likely to be in professional occupations
and less materially deprived than those agreeing to random-
ization, but were otherwise almost identical. In the extended
comprehensive cohort, socio-demographic characteristics
were very similar between the randomized and ‘‘advanced
cancer’’ or ‘‘excluded-other’’ groups, but the groups were
different clinically, representing a wider range of patients
who would receive the RCT treatments or other approaches
such as hormone therapy in routine practice.
This study had several strengths and limitations. Many
RCTs fail to include sufficient numbers of older people,
women, ethnic minorities, and those with greater depriva-
tion [28]. The prospective study recruited in areas outside
London with very small numbers from ethnic minorities,
and participation rates were proportionate to those popula-
tions [27]. The lack of diversity is a limitation in terms of
wider representativeness, although treatment outcomes
have recently been shown to be similar between ethnic
groups in the United States [29]. More deprived individuals
were less likely to respond at each stage in the prospective
study, suggesting that new approaches to encourage partic-
ipation of these groups are required.
Recruitment is challenging for many RCTs [30]. It has
been suggested that pragmatic RCTs requiring ‘‘usual care’’
comparators should be embedded in prospective cohort
studies in which participants have already consented to take
part: ‘‘cohort multiple RCTs’’ [31]. This design could allow
many RCTs to be conducted, although only among those
agreeing tomultiple study participation and thus not address-
ing important issues of response bias. Other design solutions
to recruitment difficulties include ‘‘preference’’ designs
where intervention preferences are elicited, and those
without strong views are randomized [32], or comprehensivecohorts, where those who decline randomization and choose
a treatment are also followed-up alongside those randomized
[22]. Each design raises ethical and practical issues, but suc-
cessful examples [33] indicate that they can produce consid-
erable data to assess generalizability and so should be further
explored practically and methodologically.
Baseline characteristics were well balanced between the
arms in both CAP [18] and ProtecT [19] RCTs, with high
levels of retention and follow-up indicative of good internal
validity and the robustness of the findings. Another strength
of ProtecT was the high level of randomization of eligible
participantsdat 62%, much higher than the similar Prosta-
tectomy versus Observation Trial (14.6%) [17] and most
other cancer RCTs [34]. This was achieved by the integra-
tion of qualitative research to optimize recruitment and
informed consent [21,35] and dedicated staff training
[36]. Men who declined randomization were very similar
to the randomized in almost every aspect, except for having
more professional occupations and lower deprivation.
These patients, choosing treatments as they would in usual
care, along with the extended comprehensive cohort of pa-
tients excluded from the RCT but likely to be encountered
in routine care, will provide many opportunities for analysis
of clinical relevance and generalizability in due course.
It will be important to assess the impact of changes in
PCa diagnosis since recruitment, such as the introduction
of multi-parametric magnetic resonance imaging [37].
There have also been changes in treatment techniques,
including robot-assisted surgery and developments in radio-
therapy and methods of active surveillance, although recent
evaluations of short- and medium-term oncological and
patient-reported functional outcomesdexpected to be bet-
ter with newer techniquesdhave produced remarkably
similar results to ProtecT [38e40], suggesting ProtecT’s
continuing clinical relevance. A recent English national
audit showed that the majority of patients receiving surgery
in 2014e2015 had a much higher grade and stage profile
than those in ProtecT [41]dbut the audit included men
diagnosed clinically with symptoms as well from low-
background PSA testing (around 6% p.a. in the UK [42]).
The small number of men with high-risk PCa randomized
in ProtecT is a limitation, but some of these were included in
the extended comprehensive cohort ‘‘advanced’’ and
‘‘excluded’’ groups, followed-up observationally [43]. The
prospective study suggested that other high-risk men had
moved earlier into routine care through previous PSA testing
or urological treatment (Table 1), and others would be among
those who declined the PSA-test invitation at the outset. The
ProtecT findings are likely to be most relevant for men with
low- and intermediate-risk PCa and fit for treatment, who
represent a large proportion of cases diagnosed in the UK,
and even higher proportions in many parts of Europe and
North America where higher levels of PSA testing occur.
The PRECIS-2 tool provides support for trialists to
discuss intentions to be more or less pragmatic and be
clearer about the influence of design choices on
45J.L. Donovan et al. / Journal of Clinical Epidemiology 96 (2018) 35e46applicability [6], but some have suggested that, although
useful, this is only the first stage, and that operational chal-
lenges (and solutions) during trial conduct can have a
greater impact on a trial’s generalizability [10,13]. The Pro-
tecT and CAP RCTs were designed long before these tools/
guidelines were available. Although they would undoubt-
edly have been helpful, we would suggest that alongside
these tools/guidelines at the design stage, trialists should
also ensure that they collect robust data that will later
permit evidence-based insights into generalizability.
Such design decisions will inevitably have an impact on
resources, but adding comprehensive-cohort studies and ex-
tending them as in this study are likely to provide consider-
able added value at relatively little cost. A real or perceived
lack of relevance to patients in routine care continues to
contribute to the slow or limited uptake of RCT evidence
into practice [4,5]. Pragmatic RCTs need to provide appli-
cable evidence, and initiatives such as those reported in this
study are needed to provide evidence to increase clinicians’
and policy-makers’ confidence in the generalizability of
trial findings.5. Conclusions
Even the most pragmatic RCTs have limitations in terms
of generalizability, but it is usually difficult to determine
whether these relate to decisions made at the time of
design, during trial conduct, or because of changes in clin-
ical practice. Although some of these issues may be miti-
gated through the use of tools such as PRECIS-2 or
guidelines when making design decisions, the scale and
scope of most pragmatic RCTs mean that unanticipated
limitations will arise before the outcomes are published.
The assessment of the generalizability of the findings of
an RCT requires wide-ranging judgments about the design
and conduct of the RCT, the characteristics of its partici-
pants, and the relevance of the interventions and outcomes
in the context of contemporary clinical practice. The
embedding of the ProtecT RCT in a prospective study
and with an extended comprehensive cohort, enabled data
to be collected to support evidence-based judgments by cli-
nicians and policy-makers about the generalizability of the
randomized outcomes to patients in routine practice. With
increasing willingness to undertake pragmatic RCTs to
inform policy and practice, and tools to assist design and
implementation, attention now also needs to be devoted
to ensuring the collection of data that will provide insights
into the generalizability of the randomized findings and
facilitate the application of evidence more easily into clin-
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